Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Thalidomide for Multiple Myeloma
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00038233
- Locations
- 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00038181
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Thalidomide-Dexamethasone for Multiple Myeloma
- First Posted Date
- 2002-05-29
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 83
- Registration Number
- NCT00038090
- Locations
- 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Blood and Marrow Transplant Clinical Research Network
- Conditions
- Bone Marrow TransplantationHematopoietic Stem Cell TransplantationLeukemiaMultiple MyelomaMyelodysplastic SyndromesGraft vs Host DiseaseBlood Disease
- First Posted Date
- 2001-09-07
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Registration Number
- NCT00023530
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California at San Diego, La Jolla, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome
- Conditions
- HIV InfectionsHIV Wasting Syndrome
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 75
- Registration Number
- NCT00002127
- Locations
- 🇺🇸
Marin County Specialty Clinic, Greenbrae, California, United States
🇺🇸Gottlieb Med Group, Sherman Oaks, California, United States
🇺🇸George Washington Univ Med Ctr, Washington, District of Columbia, United States
A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 12
- Registration Number
- NCT00002392
- Locations
- 🇺🇸
Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ, New York, New York, United States
Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Target Recruit Count
- 20
- Registration Number
- NCT00002174
- Locations
- 🇺🇸
Ochsner Clinic, New Orleans, Louisiana, United States
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
- Conditions
- HIV InfectionsHIV Wasting Syndrome
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Registration Number
- NCT00002157
- Locations
- 🇺🇸
Celgene Corp, Warren, New Jersey, United States
Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV
- Conditions
- Mycobacterium Avium-Intracellulare InfectionHIV InfectionsTuberculosis, Mycobacterium Infection
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Aaron Diamond AIDS Research Center
- Registration Number
- NCT00002104
- Locations
- 🇺🇸
Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ, New York, New York, United States
🇺🇸Bellevue Hosp Ctr, New York, New York, United States
Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection
- Conditions
- HIV InfectionsStomatitis, Aphthous
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 164
- Registration Number
- NCT00000790
- Locations
- 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Louis A Weiss Memorial Hosp, Chicago, Illinois, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.